Table 3.
Overview on the pharmacological profile of mitoplast Ca2+ currents
| Target | Compound to be tested ( M) | Concentration | Inhibition of i-MCC | Inhibition of xl-MCC | Inhibition of b-MCC |
|---|---|---|---|---|---|
| MCU | Ruthenium red | 1 | None | Moderate | None |
| 10 | Moderate | Strong | Moderate | ||
| 30 | Strong | Strong | Strong | ||
| NCXmito | CGP 37187 | 10 | None | None | None |
| PTP | Cyclosporin A | 10 | None | None | None |
| (B)KCa | Paxilline IbTX | 1 0.1 | None | None | None |
| None | None | None | |||
| K ATP | Glibenclamide | 10 | None | None | None |
| Cl channels | DIDS | 100 | None | None | None |
| Nonselective cation channels | Niflumic acid | 100 | None | None | None |
The inhibitory potential of the compounds on i-MCC, xl-MCC, and b-MCC were evaluated in experiments using PS1 and PS2 in the pipette. Experiments were performed in mitoplasts of at least five different isolation days.Mitoplasts were isolated from HeLa cells as described under “Materials and methods”